Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148782 | 0.83 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4341048 | 0.81 | MEN1 (0.42) | GAAMGAMSIMGAM2ALDH1A1 | |
| Methylene Chloride SCHEMBL3176439 | 0.80 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL548470 | 0.79 | MEN1 (0.45) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL485867 | 0.79 | MEN1 (0.45) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL10723443 | 0.78 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13399149 | 0.78 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4288701 | 0.78 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL181945 | 0.76 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| Heptane SCHEMBL6925620 | 0.76 | NAAA (0.40) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026333-B1 | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060040974-A1 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-02-23 | — | — | US | disclosed |
| US-6538006-B1 | N-heterocyclic moiety-containing hydroxyethylamine protease inhibitor compounds, methods for making the compounds, and intermediates useful in the method. Also, a method for inhibiting retroviral proteases and for treatment of | PHARMACIA CORPORATION | 2003-03-25 | — | — | US | disclosed |
| US-6080743-A | AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS | NOVARTIS AG (CH) | 2000-06-27 | — | — | US | disclosed |
| EP-0182152-B1 | Antitumor antibiotics (LL-E33288 Complex) | AMERICAN CYANAMID CO (US) | 1999-05-26 | — | — | EP | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996002553-A2 | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1996-02-01 | — | — | WO | disclosed |
| US-5108912-A | Aerobic fermentation of micromonospora in liquid medium containign source of carbon, mitrogen, inorganic salts and bromine or iodine | AMERICAN CYANAMID COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| US-4970198-A | MICROMONOSPORA; ANTICARCINOGENIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1990-11-13 | — | — | US | disclosed |
| EP-0182152-A2 | Antitumor antibiotics (LL-E33288 Complex) | AMERICAN CYANAMID COMPANY (US) | 1986-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040974-A1 | Retroviral protease inhibitors | PREP, TMPRSS15, DNPEP | GAA 220/4885MGAM 633/4885SI 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.